Colorectal Cancer

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the combination of durvalumab (Imfinzi) and tremelimumab in patients with metastatic colorectal cancer (mCRC).

Michael J. Overman, MD, highlights new combination agents under investigation for the treatment of patients with GI cancers—specifically CRC—and challenges that still need to be addressed.

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Karmanos Cancer Institute, discusses patient selection criteria for adjuvant therapy in colorectal cancer (CRC).

Pashtoon M. Kasi, MD, MBBS, MS, an assistant professor of Oncology and senior associate consultant in the Division of Hematology/Oncology, Mayo Clinic, discusses the rising incidence of colorectal cancer (CRC).

The FDA has cleared a direct-to-consumer genetic test for a risk report on MUTYH-associated polyposis, a hereditary colorectal cancer syndrome.

Tanios Bekaii-Saab, MD, discusses ways to further develop precision medicine within the treatment of patients with gastrointestinal cancers.

Diwakar Davar, MD, assistant professor of medicine, Department of Medicine, Hematology/Oncology, University of Pittsburgh, discusses the rationale for the combination of anti-TIM-3 and anti-PD-1 in multiple tumor types.

The combination use of durvalumab and tremelimumab plus best supportive care prolonged median overall survival by 2.5 months compared with supportive care alone in patients with advanced refractory colorectal cancer.

The PD-L1 inhibitor durvalumab achieved objective responses in about a fourth of patients with microsatellite instability-high advanced solid tumors, including colorectal cancer.

Clinical outcomes with the combination of encorafenib, binimetinib, and cetuximab exceed historic data in patients with BRAF V600E-mutant metastatic colorectal cancer.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rarity of fusions in patients with colorectal cancer (CRC).

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Karmanos Cancer Institute, discusses optimal adjuvant therapy for the treatment of patients with colorectal cancer.

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses progress made with immunotherapy agents in gastrointestinal (GI) cancer.

Pashtoon M. Kasi, MD, MBBS, MS, an assistant professor of Oncology and senior associate consultant in the Division of Hematology/Oncology, Mayo Clinic, discusses treatment approaches for patients with metastatic colorectal cancer.

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses findings from a multicenter, single-arm phase II clinical trial evaluating the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer (CRC).

John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses the value of liquid biopsies in the treatment of patients with colorectal cancer (CRC).

During a recent OncLive Peer Exchange®, a panel of CRC experts discussed the heterogeneity of metastatic CRC and the need to identify patient subsets within this disease to enable a precision medicine approach.

The Japan Pharmaceuticals and Medical Devices Agency has approved pembrolizumab for 5 new indications, including melanoma, advanced microsatellite instability-high tumors, and 3 expanded uses in advanced non–small cell lung cancer.

Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses the rationale for the CORRELATE trial in metastatic colorectal cancer.

Pashtoon M. Kasi, MD, MBBS, MS, discusses advances and unmet needs in metastatic colorectal cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses resistance to targeted therapy in the treatment of patients with colorectal cancer.

Approximately 1 of every 20 Americans will be diagnosed with colorectal cancer at some point in their life, and the American Cancer Society estimates that most colorectal cancer deaths can be prevented by screening.

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses next steps with immunotherapy in the treatment of patients with metastatic colorectal cancer.

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the potential for immunotherapy in metastatic colorectal cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the challenges of bringing a precision medicine approach into the clinic in colorectal cancer.